Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 296 Show results per page	View Search Criteria \| Help With Results


1.		Pre-Operative Chemo (CPT11, Cisplatin), Radiotherapy, Plus Surgery for Resectable Esophageal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Other				02-0484-C NCT00160875


2.		Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				20 to 75				Pharmaceutical / Industry				01023010 / TOP-003 NCT00284258

Last Modified: 12/1/1998


3.		Phase III Randomized Study of Irinotecan vs Irinotecan/Fluorouracil/Leucovorin vs Fluorouracil/Leucovorin for Untreated Metastatic Colorectal Cancer (Summary Last Modified 12/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				MSKCC-95051 P-UPJOHN-MSKCC-95051, NCI-V96-0913

Last Modified: 5/17/2007 First Published: 5/1/1998


4.		Phase III Randomized Study of Leucovorin Calcium Plus Fluorouracil With Either Irinotecan or Oxaliplatin in Patients With Recurrent Metastatic Colorectal Cancer (Summary Last Modified 05/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 75				Pharmaceutical / Industry				FRE-GERCOR-C97-3/CPTF308 FRE-C97-3/CPTF301, FRE-C97-3/CPTF308, RP-FRE-C97-3/CPTF308, EU-97044, NCT00003260

Last Modified: 9/10/2008 First Published: 5/1/1999


5.		Phase III Randomized Study of Fluorouracil and Leucovorin Calcium With or Without Irinotecan Following Curative Resection in Patients With Stage III Colon Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI				CLB-89803 CAN-NCIC-CO15, E-89803, NCCTG-C89803, SWOG-C89803, NCT00003835, C89803, CO15

Last Modified: 6/1/2007 First Published: 3/1/2000


6.		Phase III Randomized Study of High-Dose Fluorouracil and Leucovorin Calcium With or Without Irinotecan in Patients With Metastatic Adenocarcinoma of the Colon or Rectum (Summary Last Modified 02/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over								EORTC-40986 NCT00004885

Last Modified: 6/18/2008 First Published: 4/1/2000


7.		Phase III Randomized Study of Irinotecan Versus Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Patients With Advanced Colorectal Cancer Previously Treated With Fluorouracil

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				NCCTG-N9841 ECOG-N9841, SWOG-N9841, NCT00005036, N9841

Last Modified: 6/12/2007 First Published: 7/1/2000


8.		Phase III Randomized Study of Adjuvant Leucovorin Calcium and Fluorouracil With or Without Irinotecan in Patients With Resected Stage III Colon Cancer at High Risk of Recurrence

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 75				Other				FRE-FNCLCC-ACCORD-2 FFCD-9802, EU-20014, NCT00005979

Last Modified: 2/8/2007 First Published: 8/1/2000


9.		Phase III Study of Fluorouracil, Leucovorin Calcium, and Irinotecan in Patients With Metastatic, Locally Advanced, or Recurrent Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				Not specified				NCI				CLB-9864 E-C9864, NCT00006103, C9864

Last Modified: 3/1/2001 First Published: 9/1/2000


10.		Phase III Randomized Study of Octreotide in the Prevention of Diarrhea Induced By Irinotecan in Patients With Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Closed				18 and over				Pharmaceutical / Industry				NOVARTIS-CSMS995US05 NCT00006269

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute